Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume -, Issue -, Pages ard-2023-224623
Publisher
BMJ
Online
2023-11-03
DOI
10.1136/ard-2023-224623
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
- (2023) Bernhard Hellmich et al. ANNALS OF THE RHEUMATIC DISEASES
- Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
- (2023) Rona M Smith et al. ANNALS OF THE RHEUMATIC DISEASES
- Score to assess the probability of relapse in granulomatosis with polyangiitis and microscopic polyangiitis
- (2023) Maxime Samson et al. RMD Open
- Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases
- (2022) Jerome Hadjadj et al. ANNALS OF THE RHEUMATIC DISEASES
- Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission
- (2022) Gabriele Gamerith et al. ANNALS OF THE RHEUMATIC DISEASES
- Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
- (2021) Ingrid Jyssum et al. Lancet Rheumatology
- Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis
- (2020) Pierre Charles et al. RHEUMATOLOGY
- Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
- (2020) Hendrik Schulze-Koops et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
- (2020) Pierre Charles et al. ANNALS OF INTERNAL MEDICINE
- How to estimate the effect of treatment duration on survival outcomes using observational data
- (2018) BMJ-British Medical Journal
- How to estimate the effect of treatment duration on survival outcomes using observational data
- (2018) BMJ-British Medical Journal
- Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides
- (2018) Benjamin Terrier et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type
- (2015) Sebastian Unizony et al. ANNALS OF THE RHEUMATIC DISEASES
- Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
- (2014) Loïc Guillevin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
- (2013) Ulrich Specks et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
- (2012) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Dynamic Regime Marginal Structural Mean Models for Estimation of Optimal Dynamic Treatment Regimes, Part I: Main Content
- (2010) Liliana Orellana et al.
- Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
- (2010) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
- (2010) Rachel B. Jones et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More